Vertex Keeps Outlook Despite Beating Views

 Vertex Pharmaceuticals (VRTX) retained its full-year outlook Monday despite beating quarterly expectations, and VRTX stock toppled in late trades.

For the year, the company still expects $9.55 billion to $9.7 billion in product sales. That doesn't include other sources of revenue, such as  licensing deals or royalties. The guidance is in line with analyst projections for nearly $9.7 billion.

In after-hours trading on today's stock market, VRTX stock fell 2.2% near 337.50.

Vertex is the leading maker of cystic fibrosis treatments. Product sales climbed 13% to $2.37 billion and beat forecasts for $2.34 billion. The company's triple regimen, dubbed Trikafta in the U.S., brought in the lion's share of sales at nearly $2.1 billion. Other CF treatments generated $278.1 million in sales.

The company's adjusted earnings declined 13% to $3.05 per share, but were still above projections for $3.01 a share, according to FactSet.

"Vertex delivered a strong start to 2023, with outstanding execution across our business," Chief Executive Reshma Kewalramani said in a written statement.

She noted Vertex and partner Crispr Therapeutics (CRSP) have finished filing their request for approval of a CRISPR-based gene-editing treatment for two blood diseases. Approval of that treatment, dubbed exa-cel, could buoy VRTX stock.

"Over the course of this year, we look forward to continuing to expand our leadership in CF, preparing for near-term launches, including exa-cel and advancing multiple potentially transformative medicines through mid- and late-stage clinical trials," she said.

https://www.investors.com/news/technology/vrtx-stock-vertex-earnings-q1-2023/